{rfName}
A

Indexed in

License and use

Icono OpenAccess

Citations

159

Altmetrics

Analysis of institutional authors

Fernandez-Juarez, GAuthorOrtiz, AAuthorEgido, JAuthor

Share

November 6, 2015
Publications
>
Article
Sí

A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study

Publicated to:Clinical Kidney Journal. 8 (5): 503-10-510 - 2015-10-01 8(5), DOI: 10.1093/ckj/sfv075

Authors: Rojas-Rivera J, Fernández-Juárez G, Ortiz A, Hofstra J, Gesualdo L, Tesar V, Wetzels J, Segarra A, Egido J, Praga M

Affiliations

Charles Univ Prague, Sch Med 1, Dept Nephrol, Prague, Czech Republic      Charles University Prague - Author
FRIAT, Madrid, Spain       - Author
Gen Univ Hosp, Prague, Czech Republic      General University Hospital Prague - Author
Hosp Univ Fdn Alcorcon, Div Nephrol, Madrid, Spain      Alcorcon Foundation University Hospital - Author
Hosp Valle De Hebron, Div Nephrol, Barcelona, Catalonia, Spain      Hospital Universitari Vall d'Hebron - Author
Radboud Univ Nijmegen, Med Ctr, Dept Nephrol, Nijmegen, Netherlands      Radboud University Nijmegen       - Author
Spanish Renal Res Network REDINREN, Madrid, Spain - Author
Struttura Complessa Nefrol Dialisi & Trapianto Os, Foggia, Italy - Author
Univ Autonoma Madrid, Sch Med, IIS Fdn Jimenez Diaz, Div Nephrol & Hypertens, Madrid, Spain      Fundacion Jimenez Diaz    Autonomous University of Madrid       - Author
Univ Complutense Madrid, Hosp Univ Octubre 12, Div Nephrol, Madrid, Spain      Hospital Universitario 12 de Octubre    Complutense University of Madrid - Author
      Spanish Renal Res Network REDINREN, Madrid, Spain. - Author
See more

Abstract

Patients with primary membranous nephropathy (MN) and persistent nephrotic syndrome have a high risk of progression to end-stage renal disease. The Ponticelli protocol (steroids with alkylating agents) is the most effective immunosuppressive therapy for this condition, but it has severe adverse effects. Tacrolimus and rituximab have demonstrated efficacy for remission of nephrotic syndrome in MN with a safer profile. However, the published evidence is largely based on small or short-term observational studies, historical cohorts, comparisons with conservative therapy or clinical trials without appropriate control groups, and there is no head-to-head comparison with the Ponticelli protocol.The STARMEN randomized clinical trial will compare the efficacy of sequential tacrolimus-rituximab therapy with a modified Ponticelli protocol (steroids plus cyclophosphamide). The trial will also evaluate the role of antibodies against the M-type phospholipase A2 receptor (anti-PLA2R) and other antibodies as markers of response to treatment and long-term prognosis.The trial has already started with 23 patients having been enrolled as of 1 April 2015, an estimated 21.7% of the estimated sample.

Keywords

biomarkerimmunosuppressionmembranous nephropathynephrotic syndromeBiomarkerImmunosuppressionMembranous nephropathyNephrotic syndromeRandomized controlled trial

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Clinical Kidney Journal, Q3 Agency Scopus (SJR), its regional focus and specialization in Nephrology, give it significant recognition in a specific niche of scientific knowledge at an international level.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations from Scopus Elsevier, it yields a value for the Field-Weighted Citation Impact from the Scopus agency: 3.77, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Field Citation Ratio (FCR) from Dimensions: 10.48 (source consulted: Dimensions Oct 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-10-09, the following number of citations:

  • WoS: 35
  • Scopus: 46
  • Europe PMC: 19
  • Google Scholar: 55

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-10-09:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 40.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 40 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 9.5.
  • The number of mentions on the social network X (formerly Twitter): 9 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
  • Assignment of a Handle/URN as an identifier within the deposit in the Institutional Repository: https://repositorio.uam.es/handle/10486/672108

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Czech Republic; Italy; Netherlands.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Rojas-Rivera, J) .